Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis

Clinical and Experimental Rheumatology

Volumn 26, Issue 3 SUPPL. 49, 2008, Pages

  Guignard, Sandra ^a,c   Gossec, Laure ^a   Bandinelli, Francesca ^b   Dougados, Maxime ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CENTRE HOSPITALIER DE MEAUX   (France)

Author keywords

Anti TNF; Retrospective; Rheumatoid arthritis; Vasculitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; BRAIN VASCULITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS VASCULITIS; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC VASCULITIS; VASCULITIS; VISCERAL VASCULITIS;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 52049101372     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. KLIPPEL JH, DIEPPE PA (Eds.): Rheumatology, 2nd ed. London: Mosby, 1998; 5.4.6.
2. COHEN G, COURVOISIER N, COHEN JD, ZALTNI S, SANY J, COMBE B: The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 795-800.
3. KVIEN TK, HEIBERG, LIE E et al.: A Norwegian DMARDs register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S188-94.
4. EDREES AF, MISRA SN, ABDOU NI: Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: Correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 2005; 23: 469-74.
5. MARAVIC M, BERGE C, DAURES JP, BOISSIER MC: Practices for managing a flare of long-standing rheumatoid arthritis: Survey among French rheumatologists. Clin Exp Rheumatol 2005; 23: 36-42.
6. DEN BROEDER MAA, VAN DEN HOOGEN FHJ, VAN DE PUTTE LBA: Isolated digital vasculitis in a patient with rheumatoid arthritis: Good response to tumour necrosis factor alpha blocking treatment. Ann Rheum Dis 2001; 60: 538-9.
7. BARTOLUCCI P, RAMANOELINA J, COHEN P et al.: Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: An open pilot study on 10 patients. Rheumatology 2002; 41: 1126-32.
8. BRION PH, MITTAL-HENKLE A, KALUNIAN KC: Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999; 131: 634.
9. GALARIA NA, WERTH VP, SCHUMACHER HR: Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000; 27: 2041-4.
10. MCCAIN ME, QUINET RJ, DAVIS WE: Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology. 2002; 41: 116-7.
11. LIVERMORE PA, MURRAY KJ: Anti-tumour necrosis factor therapy associated with cutaneous vasculitis. Rheumatology 2002; 41: 1450-2.
12. CUNNANE G, WARNOCK M, FYE KH, DAIKH DI: Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum 2002; 47: 445-9.
13. JARRETT SJ, CUNNANE G, CONAGHAN PG et al.: Anti-tumor necrosis factor-alpha therapy-induced vasculitis: Case series. J Rheumatol 2003; 30: 2287-91.
14. MOHAN N, EDWARDS ET, CUPPS TR et al.: Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004; 31: 1955-8.
15. RICHETTE P, DIEUDE P, DAMIANO J, LIOTE F, ORCEL P, BARDIN T: Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol 2004; 31: 2079-81.
16. BEGAUD B: Standardised assessment of adverse Trug reactions: the method used in France. Drug Inf J 1984; 18: 275-81.
17. ARNETT FC, EDWORTHY SM, BLOCK DA et al.: The American Rheumatism association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-23.
18. SCOTT DGI, BACON PA: Intravenous cyclophosphamide plus methyl prednisolone in the treatment of systemic rheumatoid vasculitis. Am J of Med 1984; 76: 377-84.
19. BALSA A, CARMONA L, GONZALEZ-ALVARO I, BELMONTE MA, TENA X, SANMARTI R; EMECAR STUDY GROUP: Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004; 31: 40-6.
20. GUILLEVIN L, MOUTHON L: Tumor necrosis factor-alpha blockade and the risk of vasculitis. J Rheumatol 2004; 31: 1885-7.
21. TURESSON C, MCCLELLANO RL, CHRISTIANSON TJ, MATTESON EL: No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: Results from a community-based study. Arthritis Rheum 2004; 50: 3729-3.